ST Weiming disclosed its earnings forecast, expecting a net loss attributable to the parent company of 90 million to 120 million yuan in the first half of 2026, compared with a loss of 67.3027 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 89 million to 119 million yuan, compared with a loss of 67.1924 million yuan a year earlier. Basic earnings per share are projected to be between negative 0.1364 yuan and negative 0.1819 yuan. The company stated that the loss is mainly due to the suspension of production and sales at its subsidiary Tianjin Weiming and the impact of pharmaceutical industry policies.
Shandong Sinobioway Biomedicine Co LtdPharmaceutical industry policies are cited as a cause of loss, but the company is not directly mentioned.